drugset / Trial / NCT05076097
A Study of OLR in First-line Treatment of Mantle Cell Lymphoma
NaSingle-groupOpen-labelTreatment
Summary
This is a single-arm, multicenter, open label phase II clinical study to evaluate the efficacy and safety of OLR in the treatment of initially treated mantle cell lymphoma.
Timeline
- Start
- 2021-09-30
- Primary completion
- 2022-10-15
- Completion
- 2023-10-15
Publications
- Background 2020 ASH, poster 2042
- Background EHA 2020-Abstract S228
- Results Al-Hamadani M, Habermann TM, Cerhan JR, Macon WR, Maurer MJ, Go RS. Non-Hodgkin lymphoma subtype distribution, geodemographic patterns, and survival in the US: A longitudinal analysis of the National Cancer Data Base from 1998 to 2011. Am J Hematol. 2015 Sep;90(9):790-5. doi: 10.1002/ajh.24086. Epub 2015 Jul 27.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lenalidomide | Other / unclassified | 15 mg | — |
| Subject | Orelabrutinib | Small molecule | 150 mg | — |
| Subject | Rituximab | Monoclonal antibody | 375 mg/m2 | — |